Masin D - Search Results

1

Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.

Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Warburton C, et al. Among authors: masin d. Clin Cancer Res. 2004 Apr 1;10(7):2512-24. doi: 10.1158/1078-0432.ccr-03-0244. Clin Cancer Res. 2004. PMID: 15073131

2

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

Waterhouse DN, Gelmon KA, Masin D, Bally MB. Waterhouse DN, et al. Among authors: masin d. J Exp Ther Oncol. 2003 Sep-Oct;3(5):261-71. doi: 10.1111/j.1533-869x.2003.01099.x. J Exp Ther Oncol. 2003. PMID: 14696623

3

In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.

Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. Abraham SA, et al. Among authors: masin d. Clin Cancer Res. 2004 Jan 15;10(2):728-38. doi: 10.1158/1078-0432.ccr-1131-03. Clin Cancer Res. 2004. PMID: 14760096

4

HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.

Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. Dragowska WH, et al. Among authors: masin d. Mol Cancer Res. 2004 Nov;2(11):606-19. Mol Cancer Res. 2004. PMID: 15561777

5

Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267.

Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strut D, Osooly M, Masin D, Bally MB. Kalra J, et al. Among authors: masin d. Cancer Biol Ther. 2011 May 1;11(9):826-38. doi: 10.4161/cbt.11.9.15183. Epub 2011 May 1. Cancer Biol Ther. 2011. PMID: 21358264 Free PMC article.

6

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB. Dragowska WH, et al. Among authors: masin d. BMC Cancer. 2011 Oct 1;11:420. doi: 10.1186/1471-2407-11-420. BMC Cancer. 2011. PMID: 21961653 Free PMC article.

7

Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.

Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Dos Santos N, et al. Among authors: masin d. J Control Release. 2005 Jun 20;105(1-2):89-105. doi: 10.1016/j.jconrel.2005.03.007. J Control Release. 2005. PMID: 15878792

8

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.

Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT. Verreault M, et al. Among authors: masin d. BMC Cancer. 2011 Apr 8;11:124. doi: 10.1186/1471-2407-11-124. BMC Cancer. 2011. PMID: 21477311 Free PMC article.

9

Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.

Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Mayer LD, et al. Among authors: masin d. Cancer Res. 1990 Feb 1;50(3):575-9. Cancer Res. 1990. PMID: 2297698

10

Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.

Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Mayer LD, et al. Among authors: masin d. Cancer Res. 1989 Nov 1;49(21):5922-30. Cancer Res. 1989. PMID: 2790807

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters